ImmuCell

ImmuCell Enterprise Value

The Enterprise Value (EV) of ImmuCell (ICCC) as of Oct 8, 2026 is 69.09 M USD. In the previous year, Enterprise Value (EV) was 71.04 M USD — a change of -2.75% (lower).

Enterprise Value

69.09 MUSD

YoY

-2.75%

Last updated:

Enterprise Value (EV) of ImmuCell is 2025 69.09 M USD. Enterprise Value (EV) of ImmuCell was 2024 71.04 M USD. It decreases by -2.75% lower compared to the previous year.

The ImmuCell Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
66.95 M USD
Jan 1, 2019
59.35 M USD
Jan 1, 2020
62.49 M USD
Jan 1, 2021
59.79 M USD
Jan 1, 2022
66.39 M USD
Jan 1, 2023
75.41 M USD
Jan 1, 2024
71.04 M USD
Jan 1, 2025
69.09 M USD
The ImmuCell Enterprise Value history
YEAREnterprise ValueYoY
69.09 MUSD-2.75%
71.04 MUSD-5.80%
75.41 MUSD+13.59%
66.39 MUSD+11.04%
59.79 MUSD-4.32%
62.49 MUSD+5.29%
59.35 MUSD-11.35%
66.95 MUSD+3.22%
64.86 MUSD+24.43%
52.13 MUSD-8.50%
56.97 MUSD-0.57%
57.30 MUSD—
Access this data via the Eulerpool API

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Enterprise Value (EV) of ImmuCell is 69.09 M USD in 2025.

Enterprise Value (EV) of ImmuCell changed from 71.04 M USD to 69.09 M USD, representing a -2.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) ImmuCell since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s ImmuCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — ImmuCell

All Key Metrics — ImmuCell